Project Grant R01CA315460
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $460K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92161, USA
Similar Awards
- The National Cancer Institute awarded The Washington University $160,093 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate perceptions and informational needs regarding prostate cancer screening among screening-eligible men, with particular attention to racial disparities. The research addresses how men perceive the harms and benefits of prostate-specific antigen (PSA)-based screening, especially in the context of risk-stratified screening...
- The National Institutes of Health National Cancer Institute awarded the University of Oklahoma Health Sciences Center $592,731 on May 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial improving prostate cancer screening among Black men in Oklahoma through a community-based mobile health intervention. The award funds development and evaluation of the Prostate Cancer Genius App, a smartphone-based intervention delivering...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $708,377 on August 6, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a research project examining access to and clinical outcomes of radioligand therapy for prostate cancer in the U.S. veteran population. The award funds an analysis of lutetium Lu-177 vipivotide tetraxetan (LU-177), an FDA-approved radioligand therapy for castration-resistant prostate cancer. The research...
- The National Cancer Institute awarded Kaiser Foundation Hospitals $613,229 on August 26, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to advance evidence on treatment decisions for low-risk prostate cancer in the United States. Kaiser Permanente's Kaiser Foundation Research Institute, operating at its Pleasanton, California location, will conduct two parallel cohort studies evaluating long-term clinical outcomes and patient-reported outcomes associated with active...
- The National Cancer Institute awarded Cedars-Sinai Medical Center $646,784 on June 16, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the impact of exogenous hormones on prostate cancer risk, detection, and outcomes in the Veterans Affairs health system. The research examines how men taking estrogen (MTE) experience altered prostate cancer screening patterns and disease presentation compared to men with no estrogen intake. Prior work by the recipient,...
- This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...
- The National Institutes of Health National Cancer Institute awarded Weill Medical College of Cornell University $595,632 on July 17, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to optimize prostate cancer screening decision-making among men age 70 and older. The project uses mixed-methods research to understand how prostate cancer screening cessation should be tailored to patient health status in this population. Current evidence shows that while prostate cancer...
- The National Cancer Institute awarded Cedars-Sinai Medical Center $574,557 on June 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to integrate life expectancy estimates into electronic health record decision support for men with prostate cancer. The project addresses life expectancy as a critical triage factor in prostate cancer treatment planning. Life expectancy assessment determines eligibility for aggressive treatment versus observation; men with limited...
- The National Institute for Minority Health and Health Disparities awarded Icahn School of Medicine at Mount Sinai $1,329,731 on July 19, 2026, under the Minority Health and Health Disparities Research program (CFDA 93.307) to conduct EXPAND-PC, an intervention linking prostate cancer screening with socioeconomic needs assessments and community support resources for men aged 40–69 residing in New York City Housing Authority developments. The study addresses declining prostate cancer screening...
- The National Cancer Institute (part of the National Institutes of Health under the Department of Health and Human Services) awarded New York University School of Medicine $700,171 on July 16, 2026, to advance deep learning models for clinically significant prostate cancer detection on magnetic resonance imaging. The funded research addresses three specific aims: training a robust deep learning model on diverse imaging datasets to ensure consistent performance across multiple scanners, protocols,...